At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,407 enrolled
Drug / intervention
Nitazoxanide +2 moredrug
Likely dose
Nitazoxanide 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
In Brief
A Phase 3 clinical trial evaluating Nitazoxanide, Placebo, and 1 other intervention for COVID-19 and Viral Respiratory Illnesses. Completed, enrolled 1,407 participants across 26 sites.
Detailed Summary
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, Viral Respiratory Illnesses
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartMay 2020
Primary CompletionApr 2021
TodayJul 2026
First PostedApr 24, 2020
Enrollment StartMay 13, 2020
Primary CompletionApr 7, 2021
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.2 years ago
Interventions
Nitazoxanidedrug
Nitazoxanide 600 mg administered orally twice daily for six weeks
Placebodrug
Placebo administered orally twice daily for six weeks
Vitamin Super B-Complexdietary
Vitamin Super B-Complex administered orally twice daily to maintain the blind